Methods are provided for improving the yield of aromatics during conversion of oxygenate feeds. An oxygenate feed can contain a mixture of oxygenate compounds, including one or more compounds with a hydrogen index of less than 2, so that an effective hydrogen index of the mixture of oxygenates is between about 1.4 and 1.9. Methods are also provided for converting a mixture of oxygenates with an effective hydrogen index greater than about 1 with a pyrolysis oil co-feed. The difficulties in co-processing a pyrolysis oil can be reduced or minimized by staging the introduction of pyrolysis oil into a reaction system. This can allow varying mixtures of pyrolysis oil and methanol, or another oxygenate feed, to be introduced into a reaction system at various feed entry points.

Methods are provided for improving the yield of aromatics during conversion of oxygenate feeds. An oxygenate feed can contain a mixture of oxygenate compounds, including one or more compounds with a hydrogen index of less than 2, so that an effective hydrogen index of the mixture of oxygenates is between about 1.4 and 1.9. Methods are also provided for converting a mixture of oxygenates with an effective hydrogen index greater than about 1 with a pyrolysis oil co-feed. The difficulties in co-processing a pyrolysis oil can be reduced or minimized by staging the introduction of pyrolysis oil into a reaction system. This can allow varying mixtures of pyrolysis oil and methanol, or another oxygenate feed, to be introduced into a reaction system at various feed entry points.

The present subject matter relates to methods and apparatuses for the continuous preparation of a cumene feed for a cumene oxidation process. More specifically, the subject matter relates to a process for passing a cumene alpha-methylstyrene stream through a caustic wash column having an integrated water wash section for the removal of organic acids.

The invention relates to catalysts and their use in processes for dehydrocyclization of light paraffinic hydrocarbon feedstock to higher-value hydrocarbon, such as aromatic hydrocarbon, to dehydrocyclization catalysts useful in such processes, and to the methods of making such catalysts. One of more of the dehydrocyclization catalysts comprising a crystalline aluminosilicate zeolite having a constraint index of less than or equal to about 12, at least one Group 3 to Group 13 metal of the IUPAC Periodic Table and phosphorous.

The invention relates to catalysts and their use in processes for dehydrocyclization of light paraffinic hydrocarbon feedstock to higher-value hydrocarbon, such as aromatic hydrocarbon, to dehydrocyclization catalysts useful in such processes, and to the methods of making such catalysts. One of more of the dehydrocyclization catalysts comprising a crystalline aluminosilicate zeolite having a constraint index of less than or equal to about 12, at least one Group 3 to Group 13 metal of the IUPAC Periodic Table and phosphorous.

The disclosures herein provide compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX, formula X, formula XI, formula XII, formula XIII, formula XIV and formula XV or its pharmaceutical acceptable salts, as well as polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral administration, suppository, transdermal, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of irritable bowel syndrome (IBS), inflammatory bowel diseases or its associated complications.

The disclosures herein provide compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX, formula X, formula XI, formula XII, formula XIII, formula XIV and formula XV or its pharmaceutical acceptable salts, as well as polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral administration, suppository, transdermal, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of irritable bowel syndrome (IBS), inflammatory bowel diseases or its associated complications.

Provided is an organic light-emitting device including a first compound and a second compound that offers low driving voltage and high efficiency. The organic light-emitting device includes an emission layer between a first electrode and a second electrode, and an electron transport region between the second electrode and the emission layer. The electron transport region includes the first compound. A hole transport region between the first electrode and the emission layer includes the second compound.

Provided is an organic light-emitting device including a first compound and a second compound that offers low driving voltage and high efficiency. The organic light-emitting device includes an emission layer between a first electrode and a second electrode, and an electron transport region between the second electrode and the emission layer. The electron transport region includes the first compound. A hole transport region between the first electrode and the emission layer includes the second compound.

A membrane separator comprising a membrane is used to separate various streams in processes for separating aromatic hydrocarbons from non-aromatic hydrocarbons. Such streams can be a lean-solvent stream, a rich-solvent stream, or a hydrocarbon stream comprising both aromatic and non- aromatic hydrocarbons. The membrane separator is advantageously used in combination with an extraction sub-system including a liquid—liquid distillation column and/or an extraction distillation column.